Welcome to the Crinetics Pharmaceuticals Corporate Update Conference Call. [Operator Instructions] I will now turn the call over to Gayathri Diwakar, Head of Investor Relations. Please go ahead. Thank ...
SAN DIEGO, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced PALSONIFY U.S. unaudited and preliminary net product revenue of over $5 million for ...
Strong PALSONIFY U.S. Launch Execution Resulted in Unaudited and Preliminary Net Product Revenue of >$5 Million for Fourth-Quarter 2025, with >200 Enrollment Forms at the End of December Atumelnant ...
SAN DIEGO, Jan. 04, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that the company will host a conference call and webcast on Monday, January 5, 2026 at 8:30 ...
Crinetics Pharmaceuticals is a global pharmaceutical company committed to transforming the treatment of endocrine diseases and endocrine-related tumors through science rooted in patient needs.
Background: Beckwith–Wiedemann syndrome (BWS) is a congenital imprinting disorder characterized by macrosomia, umbilical hernia, macroglossia, and increased tumor susceptibility. DNA methylation ...
Classic congenital adrenal hyperplasia (CAH) is a condition that is passed down in families. It is a serious condition that can be deadly if not treated. One of the treatments for classic CAH is ...
Congenital adrenal hyperplasia (CAH) is a group of inherited conditions in which the adrenal glands cannot make certain hormones, most commonly due to a deficiency of the enzyme 21-hydroxylase. This ...
The treatments for both classic and nonclassic congenital adrenal hyperplasia (CAH) include medication, surgery, and psychological support, or a combination of all three. Some people who have CAH, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback